AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025
California-Based Firm Has Begun Primary Analytical Studies For ABP-450 Candidate
With an ambitious goal to file a biosimilar to the world-renowned Botox brand via the US FDA’s 351(k) regulatory pathway, AEON Biopharma has revealed the latest steps in its plan.
